The Hidden Quality-of-Life and Mental Health Burden of CIndU

"The Hidden Quality-of-Life and Mental Health Burden of CIndU" takes up a question clinicians often underestimate: how much CIndU disrupts daily life.

Dr. Cotter asks Dr. Trotter to describe the quality-of-life and mental health impact she observes. She calls the burden tremendous and widely underestimated. Studies show quality-of-life scores for chronic urticaria that are lower than those for psoriasis or atopic dermatitis. Many clinicians are surprised by this finding.

Dr. Trotter explains that the burden is multifactorial. Identifying the trigger can be stressful in itself. Once it is found, patients face a dilemma, because avoidance may mean giving up activities, clothing, or hobbies they value. Symptoms also differ by subtype. Patients with symptomatic dermographism mostly report itching, while others describe burning or stinging. Either way, symptoms disrupt sleep, which then affects performance at work and school. Fear of scratching in public, or of being seen as contagious, leads some patients to withdraw socially.

Dr. Cotter adds that symptomatic dermographism creates a vicious cycle, because scratching produces more wheals. He notes that patients are often marginalized, being told burning cannot be hives or that a positive ANA means autoimmune disease.

Dr. Finklea cites data showing an average diagnostic delay of about two years, often involving up to six providers. Patients undergo many evaluations and unnecessary laboratory tests while searching for a root cause. She also highlights a treatment adherence problem. Patients often take antihistamines reactively rather than proactively, then assume the disease has resolved when symptoms fade.

She describes patients who effectively stop living their lives, avoiding the outdoors all summer or giving up exercise entirely. Her goal is to help patients enjoy life rather than work around their disease. That requires therapies capable of delivering the highest possible level of control.

Up next, in "Trigger Avoidance and Antihistamine Up-Dosing in CIndU," the panel examines when avoidance is realistic and how to optimize antihistamines when it is not.